Latest filing published 16 Mar 2026 for MBX Biosciences, Inc., €456k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
P. Kent Hawryluk: trading record in brief
P. Kent Hawryluk has filed trades across 2 companies (mainly through SEC (Form 4)), most often in MBX Biosciences, Inc. and MetaVia Inc. Between 10 August 2016 and 13 March 2026, the trades on record add up to 13 filings.
On the market, this insider has only ever bought: 5 purchases, €1.7M in total. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 1 share grant and 2 option exercises. In 2026 alone, the filings show 1 purchase and no sales.
Half of the purchases are above €234k and half below. Of 5 purchases, 3 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.
The record was last updated on 16 March 2026 with an open-market purchase (€456k) in MBX Biosciences, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to P. Kent Hawryluk
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 18,500 shares@ US$28.414246.9% of flowCommon StockSEC:0001193125-26-107268:0Canonical exit: 11 Jun 2026 (T+90)
- 182,859 shares@ US$3.25Common StockSEC:0001193125-25-252404:0
- 20,000 shares@ US$13.6395Common StockSEC:0001193125-25-245411:0Canonical exit: 18 Jan 2026 (T+90)
- 50,000 shares@ US$10.69100.0% of flowCommon StockSEC:0000950170-25-014494:0Canonical exit: 5 May 2025 (T+90)
- 283,846 sharesCommon StockSEC:0000950170-24-107527:0
5 of 5 declarations